[A24-105] Capivasertib (breast cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 03.04.2025
Project no.:
A24-105
Commission:
Commission awarded on 01.10.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Women and men with PIK3CA/AKT1/PTEN-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer
- Women after recurrence of the disease during or after (neo-)adjuvant endocrine therapy, no treatment to date in locally advanced or metastatic stage: added benefit not proven
- Men after recurrence of the disease during or after (neo-)adjuvant endocrine therapy, no treatment to date in locally advanced or metastatic stage: added benefit not proven
- Women with disease progression during or after endocrine therapy that occurred in the locally advanced or metastatic stage: added benefit not proven
- Men with disease progression during or after endocrine therapy that occurred in the locally advanced or metastatic stage: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-105
| Project no. | Title | Status |
|---|---|---|
| A25-26 | Capivasertib (breast cancer) – Addendum to Project A24-105 | Commission completed |
| G25-06 | Capivasertib (breast cancer) – 2nd Addendum to Project A24-105 | Commission completed |
Federal Joint Committee (G-BA)
2025-04-03 A G-BA decision was published.